Miglitol-d4 is intended for use as an internal standard for the quantification of miglitol by GC- or LC-MS. Miglitol is an inhibitor of α-glucosidases (IC50s = 0.35, 0.11, 1.3, and 1.2 µM for human lysosomal α-glucosidase and rat sucrase, maltase, and isomaltase, respectively).1 It is selective for human α- over β-glucosidase (IC50 = 84 µM). Miglitol (10 mg/kg) decreases blood glucose levels in sucrose-loaded Goto-Kakizaki (GK) type 2 diabetic rats.2 Dietary administration of miglitol (40 mg/100 g diet) for 8 weeks decreases changes in HbA1c levels compared with control rats fed a normal diet. Formulations containing miglitol have been used in the treatment of type 2 diabetes.
1.Kuriyama, C., Kamiyama, O., Ikeda, K., et al.In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell culturesBioorg. Med. Chem.16(15)7330-7336(2008) 2.Goda, T., Suruga, K., Komori, A., et al.Effects of miglitol, an α-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki ratsBr. J. Nutr.98(4)702-710(2007)